Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis

Current first-line standard therapy for metastatic non-small cell lung cancer without driver mutations involves chemotherapy and immunotherapy combination. Prior to the advent of immune checkpoint inhibition, REVEL, a randomized phase III trial demonstrated improved progression-free and overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kareff, Samuel A., Gawri, Kunal, Khan, Khadeja, Kwon, Deukwoo, Rodriguez, Estelamari, Lopes, Gilberto de Lima, Dawar, Richa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072276/
https://www.ncbi.nlm.nih.gov/pubmed/37025595
http://dx.doi.org/10.3389/fonc.2023.1012783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072276/
https://www.ncbi.nlm.nih.gov/pubmed/37025595
http://dx.doi.org/10.3389/fonc.2023.1012783

Ejemplares similares